Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
用户EO9nReo4Hj6s
1个月前
64
10
已完结
1. 系统已在2026-09-09 17:49:26对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-26-00243
文献链接: https://ascopubs.org/doi/10.1200/JCO-26-00243
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Yuanyuan Zhao; Hongyun Zhao; Qiming Wang; Kunyu Yang; Yongsheng Li; Zhenming Fu; Weihua Yang; Zhiyong He; Yongsheng Wang; Yuxiang Ma; Yunpeng Yang; Wenfeng Fang; Sa Xiao; Hai Zhu; Yi Zhu; Li Zhang; Yan Huang
